Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Net Cash Flow (2016 - 2025)

United Therapeutics (UTHR) has disclosed Net Cash Flow for 17 consecutive years, with $217.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 51.43% to $217.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$140.1 million through Dec 2025, down 128.62% year-over-year, with the annual reading at -$140.1 million for FY2025, 128.62% down from the prior year.
  • Net Cash Flow hit $217.0 million in Q4 2025 for United Therapeutics, up from -$253.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $217.0 million in Q4 2025 to a low of -$306.8 million in Q2 2025.
  • Historically, Net Cash Flow has averaged $40.9 million across 5 years, with a median of $68.7 million in 2021.
  • Biggest YoY gain for Net Cash Flow was 1885.71% in 2023; the steepest drop was 431.49% in 2023.
  • Year by year, Net Cash Flow stood at -$13.7 million in 2021, then skyrocketed by 59.12% to -$5.6 million in 2022, then surged by 1885.71% to $100.0 million in 2023, then surged by 43.3% to $143.3 million in 2024, then skyrocketed by 51.43% to $217.0 million in 2025.
  • Business Quant data shows Net Cash Flow for UTHR at $217.0 million in Q4 2025, -$253.0 million in Q3 2025, and -$306.8 million in Q2 2025.